EUVIMEDEUVIMED entdecken
Open Access

Maximized sequential probability ratio test regression

Ivair R Silva iD, Joselito Montalban, Fernando L P de Oliveira

Biometrics · 2025

DOI: 10.1093/biomtc/ujaf170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2025. Verfasst von Ivair R Silva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Models, Statistical, Biometry, Vaccines, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ideally, the sequential monitoring of adverse events following post-licensed drugs and vaccines is correctly adjusted for confounding variables, such as gender and age, that may have an effect on the quality of the events. This is the idea behind the usual fully randomized, the placebo-control, and the self-control designs. Two prominent methods for conducting sequential analysis of the safety of post-market drugs and vaccines are the maximized sequential probability ratio test (MaxSPRT), and its conditional version, the CMaxSPRT. However, even when the assumption of sample homogeneity is realistic prior to the drug/vaccine administration, the effects caused by the drugs and vaccines on the risk of an adverse event, if any, can still vary according to observable covariates. For binomial and Poisson data, a straightforward sequential test method is introduced in order to accommodate a regression structure in the MaxSPRT. The proposed sequential regression test is also applicable for the CMaxSPRT, that is, the regression works for comparing historical and surveillance Poisson data with unknown heterogeneous baseline rates, taking into account seasonality and any other observable confounding covariates. To illustrate the usefulness of such a regression method, we describe the potential applications of the method to monitor vaccine-adverse events in Manitoba, Canada. The numeric results and examples were executed with the R Sequential package.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, StatisticalBiometryVaccinesDrug-Related Side Effects and Adverse ReactionsProduct Surveillance, PostmarketingHumansRegression AnalysisData Interpretation, StatisticalComputer SimulationPoisson DistributionProbability

Stichwörter der Autor:innen

adverse eventspost-market vaccine surveillanceseasonalitysequential regression

Substanzen

Vaccines

Autor:innen und Institutionen

  • Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA 02215, United States.
  • Computer Department, Federal University of Ouro Preto, Ouro Preto, MG 35400-000, Brazil.
  • Communicable Disease Control, Manitoba Health, Winnipeg, MB R3B 3M9, Canada.
  • Department of Statistics, Federal University of Ouro Preto, Ouro Preto, MG 35400-000, Brazil.

ORCID-Profile: Ivair R Silva

Förderung

  • NIGMS NIH HHS
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • National Institute of General Medical Sciences

Zitieren

APA

Silva, I. R., Montalban, J., & de Oliveira, F. L. P. (2025). Maximized sequential probability ratio test regression. Biometrics. https://doi.org/10.1093/biomtc/ujaf170

Vancouver

Silva IR, Montalban J, de Oliveira FLP. Maximized sequential probability ratio test regression. Biometrics. 2025. doi:10.1093/biomtc/ujaf170

BibTeX
@article{Silva2025,
  author = {Silva, Ivair R and Montalban, Joselito and de Oliveira, Fernando L P},
  title = {Maximized sequential probability ratio test regression},
  journal = {Biometrics},
  year = {2025},
  doi = {10.1093/biomtc/ujaf170}
}
Kostenlos starten →